Table 1.
Baseline characteristics of DLBCL patients receiving RIC/NMA conditioning regimens followed by allo-HCT between 2008–2016
| Flu/Bu N (%) | Flu/Mel 140 N (%) | BEAM N (%) | p-value | |
|---|---|---|---|---|
| Number of patients | 151 | 296 | 115 | |
| Median patient age, years (range) | 59 (25–72) | 56 (22–73) | 53 (22–69) | 0.004 |
| ≥60 | 68 (45) | 99 (33) | 23 (20) | |
| Male sex | 87 (58) | 190 (64) | 74 (64) | 0.36 |
| Karnofsky performance score ≥ 90 | 83 (55) | 175 (59) | 45 (39) | <0.001 |
| Missing | 1 (1) | 6 (2) | 10 (9) | |
| HCT-CI | 0.06 | |||
| 0 | 34 (23) | 98 (33) | 41 (36) | |
| 1–2 | 51 (34) | 72 (24) | 35 (30) | |
| ≥3 | 64 (42) | 118 (40) | 35 (30) | |
| Missing | 2 (1) | 8 (3) | 4 (4) | |
| Patient race | 0.04 | |||
| Caucasian | 142 (94) | 257 (87) | 98 (85) | |
| Other | 9 (6) | 39 (13) | 17 (15) | |
| Remission at HCT | <0.001 | |||
| CR | 68 (45) | 126 (43) | 37 (32) | |
| PR | 60 (40) | 124 (42) | 36 (31) | |
| Resistant | 16 (11) | 42 (14) | 41 (36) | |
| Untreated/Unknown | 4 (3) | 3 (1) | 0 | |
| Not reported | 3 (2) | 1 (0.3) | 1 (1) | |
| History of prior auto-HCT | 83 (55) | 133 (45) | 11 (10) | <0.001 |
| Donor type | 0.25 | |||
| Matched related donor | 70 (46) | 153 (52) | 65 (57) | |
| Matched unrelated donor | 81 (54) | 143 (48) | 50 (43) | |
| Median time from diagnosis to HCT, months (range) | 34 (3–340) | 27 (<l-386) | 14 (2–258) | <0.001 |
| GVHD prophylaxis | <0.001 | |||
| CNI + MMF+−other (s) | 40 (26) | 39 (13) | 34 (30) | |
| CNI + MTX+−other (s) | 96 (64) | 176 (60) | 62 (54) | |
| CNI + other (s) | 15 (10) | 81 (27) | 19 (16) | |
| ATG/alemtuzumab use in conditioning | 53 (35) | 71 (24) | 44 (38) | 0.005 |
| Rituximab use in conditioning | 2 (1) | 32 (11) | 56 (49) | <0.001 |
| Donor/recipient sex match | 0.29 | |||
| F-M | 25 (17) | 69 (23) | 20 (17) | |
| Other combinations | 126 (83) | 227 (77) | 94 (82) | |
| Missing | 0 | 0 | 1 (1) | |
| Donor/recipient CMV match | 0.93 | |||
| Donor-/recipient+ | 42 (28) | 79 (27) | 33 (29) | |
| Others | 108 (71) | 212 (71) | 81 (70) | |
| Not reported | 1 (1) | 5 (2) | 1 (1) | |
| Year of transplant | 0.03 | |||
| 2008 | 12 (7.9) | 12 (4.1) | 12 (10.4) | |
| 2009 | 14 (9.3) | 29 (9.8) | 14 (12.2) | |
| 2010 | 8 (5.3) | 33 (11.1) | 11 (9.6) | |
| 2011 | 14 (9.3) | 23 (7.8) | 13 (11.3) | |
| 2012 | 22 (14.6) | 31 (10.5) | 11 (9.6) | |
| 2013 | 29 (19.2) | 36 (12.2) | 18 (15.7) | |
| 2014 | 24 (15.9) | 40 (13.5) | 10 (8.7) | |
| 2015 | 13 (8.6) | 45 (15.2) | 17 (14.8) | |
| 2016 | 15 (9.9) | 47 (15.9) | 9 (7.8) | |
| Median number of lines of chemotherapy (range) | 2 (1–5) | 3 (1–5) | 3 (1–5) | 0.37 |
| Median follow-up of survivors (range), months | 48 (4–100) | 37 (2–101) | 60 (3–96) |
Abbreviations: DLBCL- Diffuse large B-cell lymphoma; RIC/NMA- Reduced Intensity Conditioning/Non-myeloablative; allo-HCT- Allogeneic hematopoietic cell transplantation; Flu/Bu- Fludarabine/Busulfan; Flu/Mel- Fludarabine/Melphalan; BEAM- BCNU/etoposide/cytarabine/melphalan; HCT-CI- Hematopoietic Cell Transplantation Specific Comorbidity Index; auto-HCT- Autologous Hematopoietic cell transplantation; GVHD- Graft versus Host Disease; CNI- Calcineurin inhibitor; MMF- Mycophenolate mofetil; MTX- methotrexate; ATG- Anti-Thymocyte Globulin.